Results 181 to 190 of about 2,872,365 (306)
The potential for biased signalling in the P2Y receptor family of GPCRs
British Journal of Pharmacology, EarlyView.The purinergic receptor family is primarily activated by nucleotides, and contains members of both the G protein coupled‐receptor (GPCR) superfamily (P1 and P2Y) and ligand‐gated ion channels (P2X). The P2Y receptors are widely expressed in the human body, and given the ubiquitous nature of nucleotides, purinergic signalling is involved with a plethora
Claudia M. Sisk +2 more
wiley +1 more source
Opioid agonist treatment for pharmaceutical opioid dependent people (Protocol)
, 2014 This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the effects of maintenance agonist pharmacotherapy treatments for the treatment of pharmaceutical opioid ...
Linda Gowing (20229114) +5 more
core
Novel approaches for drug development against chronic primary pain: A systematic review
British Journal of Pharmacology, EarlyView.Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus +5 more
wiley +1 more source
Access to opioid agonist therapy in Russia: time for reform [PDF]
The Lancet HIV, 2018 openaire +2 more sources
Comprehensive treatment of opioid addiction in patients receiving opioid agonist maintenance therapy
European PsychiatryIntroduction Opioid addiction is a chronic relapsing disorder that poses a significant threat to public health worldwide. In modern medicine, opioid agonist maintenance therapy is the gold standard of treatment.
openaire +1 more source
British Journal of Pharmacology, EarlyView.Abstract Background and Purpose Chemotherapy‐induced peripheral neuropathy (CIPN) is a prevalent and treatment‐resistant side effect of platinum‐based chemotherapy, characterised by mechanical allodynia. Cannabigerol (CBG), a non‐psychoactive cannabinoid, has shown antinociceptive potential, but its site and mechanism of action remain unclear.
Quinn W. Wade +7 more
wiley +1 more source
Background:There has been a rise in opioid abuse and related injection drug use in the United States and treatment for opioid use disorders may be underutilized.
core
Novel therapeutic targets for chronic visceral pain in gastrointestinal disorders
British Journal of Pharmacology, EarlyView.Chronic visceral pain imposes a major clinical challenge in gastroenterology and beyond, profoundly impacting patients' quality of life. However, limited understanding of its complex, multifaceted pathophysiology, encompassing both peripheral and central mechanisms, continues to impede the development of effective management strategies.
Fleur Veldman +3 more
wiley +1 more source
Cancer pain: current practice and emerging targets
British Journal of Pharmacology, EarlyView.Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye +5 more
wiley +1 more source